Agency for Healthcare Research and Quality (AHRQ)


March 01, 2012

In This Article

Comparison of Recommendations: Natriuretic Peptides

ACCF/AHA (2010)

Class III: No Benefit

Measurement of natriuretic peptides is not recommended for CHD risk assessment in asymptomatic adults (Di Angelantonio et al., 2009). (Level of Evidence: B)

NACB (2009)

  1. Increased BNP or NT-proBNP concentrations are associated with increased mortality in the next 2 to 7 years in community-based populations. However, the benefits of therapy based on these measurements are uncertain. Measurement for CVD risk assessment in the primary prevention setting is unwarranted. (Classification of recommendation: III [against measurement], Level of evidence: B)

USPSTF (2009)

No recommendations provided.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.